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A Clinical Prediction Rule to Estimate the Probability of
Mediastinal Metastasis in Patients with Non-small Cell
Lung Cancer
Shirin Shafazand, MD, MS,* and Michael K. Gould, MD, MS†‡
Introduction: Estimating the clinical probability of mediastinal
metastasis in patients with non-small cell lung cancer (NSCLC) can
facilitate the selection and interpretation of staging tests.
Purpose: We sought to identify independent clinical predictors of
mediastinal metastasis and to develop a prediction rule to estimate
the pretest probability of nodal metastasis in patients with NSCLC.
Methods: We used data from a randomized controlled trial of
selective versus routine mediastinoscopy to develop a clinical pre-
diction model.
Results: Five hundred sixty-six patients were included, with a mean
age of 65  9 years; 31% had positive lymph nodes. Independent
predictors of positive nodes included adenocarcinoma or large cell
histology (OR 2.6, 95% confidence interval [CI]  1.8–3.9), apparent
metastatic disease on chest radiography (OR 2.4, 95% CI  1.2–4.7),
central location of the primary tumor (OR 2.1, 95% CI  1.4–3.3),
symptoms from the primary tumor (OR 1.6, 95% CI 1.1–2.4), tumor
diameter 3.6 cm (OR 1.5, 95% CI  1.0–2.3), and age less than 65
years (OR 1.5, 95% CI  1.0–2.2). Model accuracy and calibration
were good, with an area under the receiver operating characteristic
curve of 0.70 (95% CI  0.66–0.75) and good agreement between
observed and predicted probabilities of mediastinal metastasis.
Conclusions: Our prediction rule can be used to estimate the pretest
probability of mediastinal metastasis in patients with NSCLC. Such
estimates can facilitate clinical decision making when selecting and
interpreting the results of noninvasive and invasive staging tests.
(J Thorac Oncol. 2006;1: 953–959)
In patients with non-small cell lung cancer (NSCLC), accu-rate staging is crucial to guide treatment decisions and to
reliably estimate prognosis. The optimal treatment and the
best chance at cure for eligible patients with NSCLC is
surgical resection. Unfortunately, patients with mediastinal
lymph node (N2) involvement are for the most part consid-
ered unresectable and are unlikely to survive for 5 years.1–4
Reliable and accurate detection of N2 disease is impor-
tant to avoid the morbidity, mortality, and costs associated
with performing unnecessary surgery in patients who will not
benefit. More importantly, accurate staging will reduce the
number of missed thoracotomies in patients with diseases that
are incorrectly classified as being unresectable. There contin-
ues to be some debate as to the most cost-effective strategy
for preoperative staging in patients with NSCLC. Some
thoracic surgeons perform mediastinoscopy routinely,
whereas others use it selectively or not at all.5–7 Minimally
invasive biopsy procedures continue to be underused.8 Anec-
dotally, positron emission tomography (PET) with F-18 flu-
orodeoxyglucose tends to be used routinely where available,
despite its high cost. Identifying patients at high or low risk
for N2 metastases may help stratify candidates for noninva-
sive and/or invasive diagnostic procedures before offering
potentially curative surgery.9
In prior research, we demonstrated that the effective-
ness and cost-effectiveness of different strategies for lung
cancer diagnosis and staging depend critically on the pretest
probability of disease.10,11 More fundamentally, it is difficult
to select and interpret diagnostic test results correctly without
making an estimate of the patient’s pretest probability. In this
study, we sought to identify independent clinical predictors of
N2 metastasis and to develop and internally validate a clini-
cally useful prediction rule to estimate the pretest probability
of N2 metastases in patients with NSCLC. It is important to
note that this model is not intended for use as a stand-alone
diagnostic test but, rather, to estimate the pretest probability
and to guide subsequent diagnostic test selection.
METHODS
We analyzed data from a randomized controlled trial of
selective versus routine mediastinoscopy that was performed
by the Canadian Lung Oncology Group. The study enrolled
685 patients with potentially resectable lung cancer from six
centers in Canada between November 1987 and September
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1990.12 Institutional review board approval and written pa-
tient consent were obtained by each participating center
before enrollment. Deidentified data were used for the pur-
poses of our study.
We identified several potential clinical predictors of N2
metastasis in the trial database that would be available to
clinicians after performing a routine clinical evaluation. In-
cluded were patient demographic characteristics; presence of
symptoms from primary tumor and N2 spread; tumor char-
acteristics such as size, location, and histology; chest radio-
graph (CXR) appearance of the mediastinum; and selected
laboratory values. Mediastinoscopy and thoracotomy results
were used to determine the presence of N2 involvement. We
included patients who had N2 metastasis confirmed by either
mediastinoscopy or thoracotomy and those in whom lymph
node metastasis was excluded by thoracotomy.
Data Analysis
We report means and standard deviations to describe
continuous variables that were normally distributed. We re-
port frequencies to describe categorical data. We performed
unpaired t tests to compare differences in continuous vari-
ables, and we performed the chi-square test statistic or Fish-
er’s exact test to compare categorical variables. We accepted
a two-tailed p value 0.05 as statistically significant for all
analyses.
We entered all potential predictors of N2 metastasis
into a multiple logistic regression model without using back-
ward or forward selection methods. We arrived at a parsimo-
nious clinical prediction rule by removing all predictor vari-
ables that had a p value 0.05.13 All variables that were not
included in the final model had odds ratios (OR) that were
close to 1 and p values 0.3. We dichotomized continuous
variables by using the median value as the cutoff point. All
clinically plausible interactions were tested, but none were
statistically significant, so they were not included in the final
model. We report OR and 95% confidence intervals (CI) for
statistically significant predictors. We generated predicted
probabilities of N2 metastasis and their 95% CI for patients,
using all possible combinations of predictor variables in the
final model.
We used the Hosmer–Lemeshow goodness-of-fit statis-
tic (p  0.05) to evaluate model fit.14,15 We evaluated the
accuracy of the final prediction equation by calculating the
area under the receiver operating characteristic (ROC)
curve.16 To assess model calibration, we divided the study
cohort into quintiles according to the predicted probability of
N2 metastasis and then plotted observed probability as a
function of predicted probability.17
We internally validated the model by using a cross-
validation procedure (modified jackknife), which enabled us
to use the full data set for model development.18 To do this,
we divided the study population into 10 equal groups by
sampling randomly without replacement. Subsequently, we
generated predicted probabilities of metastasis for individual
patients in each of the 10 groups by using data from the other
nine groups to fit models that included all variables from the
final prediction equation. We calculated the area under the
ROC curve that described the tradeoff between sensitivity
and specificity of the resulting predicted probabilities at
multiple thresholds for a positive diagnosis. All predicted
probabilities from patients in all 10 groups were used to
construct this ROC curve.
We analyzed data by using SPSS for Windows version
12.0 (SPSS, Chicago, IL) and SAS version 9.1. (SAS Insti-
tute, Cary, NC).
RESULTS
From the study cohort of 685 patients, we excluded 74
patients with a primary diagnosis other than NSCLC and 45
patients in whom N2 status was not definitively established;
566 patients met our inclusion criteria (Table 1). Positive N2
were identified in 175 (31%) patients. The mean age of
patients was 65 9 years, and 28% were women. At the time
of enrollment in the study, symptoms from the primary tumor
TABLE 1. Patient Characteristics
Characteristic All (n  566) Node Positive (n  175) Node Negative (n  391) p
Age (yr) 65  9 63  9 66  9 0.007
Gender (% female) 28 30 27 0.57
Hemoglobin (g/liter) 137  15 136  14 137  15 0.49
Symptoms from primary tumor (%) 56 66 51 0.001
Weight loss (%) 7 10 6 0.10
Symptoms from mediastinal spread (%) 5 6 5 0.48
Tumor size (cm) 3.8  1.8 4.1  1.8 3.6  1.8 0.006
Tumor location (%)
Upper lobes 71 72 70 0.64
Central location 26 38 21 0.0
Histology (%)
Squamous/mixed 50 43 53 0.03
Adenocarcinoma or large cell 42 55 36 0.0
Other 8 2 11 0.0
Mediastinal metastasis suspected on chest
radiology (%)
8 14 5 0.0
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(e.g., cough, dyspnea, and hemoptysis) were reported by 56%
of patients, 5% had symptoms from N2 spread, and 7% noted
weight loss (defined as weight loss of 10% in the preceding
6 months). The mean tumor size was 3.8  1.8 cm, with the
majority of the tumors located peripherally (74%) and in the
upper lobes (71%). Fifty percent of tumors had histology
compatible with mixed (3%) or squamous cell carcinoma
(47%), and 42% were adenocarcinomas (31%) or large cell
tumors (11%). Bronchoalveolar cell carcinoma was found in
5% of patients. Study surgeons suspected N2 metastasis on
CXR in 8% of patients.
Patients who had positive N2 were younger than node-
negative patients (mean age 63 versus 66, p  0.007) and
were more likely to report symptoms from their primary
tumor (66 versus 51%, p  0.001). There was no statistically
significant difference between the two groups in the fre-
quency of weight loss or symptoms from N2 spread. Patients
with positive N2 had larger mean tumor size (4.1 versus 3.6
cm, p 0.006) and were more likely to have centrally located
(defined as no air between the mediastinum and the lesion)
tumors (38 versus 21%, p  0.0). Fifty-five percent of the
tumors in the node-positive group were adenocarcinoma or
large cell carcinomas, compared with 36% in the node-
negative group. Patients who were node negative were more
likely than the node-positive group to have squamous cell or
mixed cell histology (53 versus 43%, p  0.03). On initial
CXR, surgeons were more likely to suspect N2 metastasis in
patients in the node-positive group (14 versus 5%, p 
0.001).
Using multiple logistic regression, we identified six
independent predictors of N2 disease (Table 2). In the final
model, adenocarcinoma or large cell histology, apparent N2
metastatic on CXR, central location of the primary tumor,
symptoms from the primary tumor, tumor diameter 3.6 cm,
and age65 years were all independently associated with the
presence of N2 metastasis. Five other potential predictors
(hemoglobin, gender, symptoms from N2 spread, weight loss,
and upper-lobe location of the primary tumor) were not
associated with N2 metastasis and were therefore not in-
cluded in the final model.
Patients with adenocarcinoma or large cell carcinoma
were approximately 2.5 times more likely than patients with
squamous cell carcinoma or mixed histology to have N2
disease at presentation, as were patients who had an abnor-
mal-looking mediastinum on CXR compared with those who
did not. Patients with centrally located lesions were approx-
imately two times more likely to have N2 metastases than
patients with peripheral tumors. Finally, patients with symp-
toms related to the primary tumor, patients with tumors 3.6
cm in diameter, and patients under 65 years of age were 1.5
times more likely than patients without these characteristics
to have positive N2.
The clinical prediction model is given by the equations:
probability of metastatis ex ⁄ 1 ex (1)
x  1.806 0.955*adeno 0.876*abnormal Cxr
 0.749*central 0.485*primary symptom
 0.435*size 0.408*age 65 (2)
where e is the base of the natural logarithm, adeno  1 if
histology is adenocarcinoma or large cell carcinoma (otherwise
0), abnormal CXR 1 if the mediastinum appears abnormal on
CXR, central  1 if the primary tumor is located in the central
third of the lung, primary symptom1 if the patient has symp-
toms attributable to the primary tumor, size  1 if the tumor is
3.6 cm in diameter, and age 65  1 if the patient is at least
65 years old.
Goodness-of-fit testing revealed that the model ac-
counted for the outcome better than chance alone (p 0.001)
and that the predicted likelihood of the outcome was similar
to the observed likelihood (p 0.61). A correlation matrix of
parameter estimates revealed no evidence of multicollinear-
ity. The accuracy of the model was good, with an area under
the ROC curve of 0.70, 95% CI 0.66 to 0.75. The predicted
probabilities that we generated with the cross-validation pro-
cedure had a similar area under the ROC curve of 0.69, 95%
CI  0.64 to 0.73.
Model calibration was excellent for patients in the first,
second, third, and fifth quintiles of predicted probability,
although the model slightly overestimated the probability of
metastasis for patients in the fourth quartile. Otherwise,
predicted probabilities closely matched the observed fre-
quency of N2 metastasis.
We used the model to generate predicted probabilities
of N2 metastasis for patients with 64 different combinations
of clinical characteristics (see Table 3 for selected combina-
tions and the Appendix for all combinations). For example, in
an asymptomatic, 70-year-old patient with a peripherally
located adenocarcinoma measuring 3.6 cm in diameter and
with no evidence of N2 metastasis on CXR, the predicted
probability of N2 disease was 22% (95% CI  16–30%). By
comparison, in a symptomatic 60-year-old patient with a
centrally located squamous cell carcinoma measuring 3.6
cm in size and an abnormal-looking mediastinum on CXR,
the predicted probability of N2 disease was 68% (95% CI 
50–81%).
DISCUSSION
Reliable and accurate detection of N2 disease is crucial
in the staging of NSCLC and is essential in preventing
unnecessary surgery in patients who will not benefit. In this
study, we identified six independent clinical predictors of N2
TABLE 2. Predictors of Mediastinal Nodal Involvement
Predictor Odds Ratio 95% CI
Adenocarcinoma or large cell 2.6 1.8–3.9
Mediastinal metastasis suspected on
chest radiology
2.4 1.2–4.7
Central location 2.1 1.4–3.3
Symptoms from primary tumor 1.6 1.1–2.4
Tumor size 3.6 cm 1.5 1.0–2.3
Age 65 yr 1.5 1.0–2.2
CI, confidence interval.
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metastasis. Importantly, we developed a novel, parsimonious
clinical prediction equation that estimates patient-specific
probabilities of N2 metastasis with good accuracy and cali-
bration. To our knowledge, this is the first quantitative model
of pretest probability for staging in NSCLC to be developed.
Other groups have identified individual predictors of
N2 disease. In a retrospective analysis of 387 patients with
NSCLC, Takamochi et al.19 found that a maximum tumor
dimension of 2 cm and carcinoembryonic antigen level of
5.0 ng/mL were statistically significant predictors of N2
involvement. Similarly, in a study of 440 patients (102 with
N2 disease), Suzuki et al.7 confirmed that tumor size (2.0
cm), an elevated carcinoembryonic antigen level, and adeno-
carcinoma histology were significant predictors of pathologic
N2 disease. Serological tumor markers were not available in
our database and, thus, were not included in our clinical
model. However, there is growing evidence that the presence
of multiple tumor markers is correlated with more advanced
disease and worse prognosis.20,21
In agreement with the studies mentioned above, we did
not find an increased frequency of N2 metastasis based on
lobar location. Other investigators have noted that lower-lobe
tumors are associated with a higher frequency of N2 disease
and upstaging after surgery.22 In our series of patients, cen-
trally located tumors were noted, for the first time, to be
significantly associated with N2 disease.
The most novel aspect of our model is that it can be
used to generate predicted pretest probabilities of N2 metas-
tasis in patients with NSCLC; such estimates can facilitate
interpretation of the results of invasive and noninvasive
staging tests. For example, we previously showed that PET
imaging with F-18 fluorodeoxyglucose has a sensitivity of
80% and a specificity of 90% for identifying N2 metastasis;
the corresponding positive and negative likelihood ratios are
8.1 and 0.2.9 Using these estimates and the likelihood ratio
form of Bayes’ theorem,23 the calculated posttest probability
of N2 involvement is approximately 70% when pretest prob-
ability is relatively low (22%) and when PET results are
positive. Thus, patients with low to moderate pretest proba-
bility clearly should not be denied potentially curative sur-
gery on the basis of positive PET results alone.
For a similar patient with a relatively low pretest
probability of 22% who has a negative PET result, the
calculated posttest probability of N2 metastasis is 6%. When
pretest probability is 68%, the posttest probability of N2
metastasis in the setting of a negative PET is 32%. In the
former case, it may be argued that a 6% probability of N2
metastasis is low enough to forgo confirmatory mediastinos-
copy and to proceed to potentially curative thoracotomy.
However, in the patient with a high pretest probability of N2
metastasis, a negative PET result clearly does not exclude N2
involvement.
Our model can also be incorporated into a formal
cost-effectiveness analysis, as has been done with a similar
equation that predicts the pretest probability of malignancy in
patients with solitary pulmonary nodules.11,24
Our prediction model has several limitations. We de-
veloped the model using data that had been collected previ-
ously. Although it would be preferable to collect data pro-
spectively, this would require substantial time, effort, and
additional funding. Instead, we chose to take advantage of the
available data from a well-designed RCT to develop the best
model possible at this time. The dataset included information
about a large number of clinical variables, but no information
about tumor markers was available.
Although computed tomography (CT) is neither highly
sensitive nor specific for mediastinal staging,9 inclusion of
CT findings may have improved the model’s predictive abil-
ity. Unfortunately, CT results were available for only half of
the patients in our sample. Despite this, clinicians can incor-
porate CT results into probability calculations by using esti-
mates of pretest probability from a slightly modified version
of our model and the likelihood ratio form of Bayes’ theo-
rem.23 The modification is required because the variable, N2
metastases suspected on CXR, is likely to be positively
correlated with the presence of enlarged lymph nodes on CT
and, therefore, not independent of the CT results. Because our
sample included relatively few patients with suspected N2
metastasis on CXR, the coefficients of all other predictor
variables were similar whether or not this variable was
included in the model. Thus, we suggest using a five-variable
model (excluding the term for suspected N2 metastasis) when






Suspected on CXR Adeno/Large Size >3.6 Age >65 Probability % 95% CI (%)
0 0 0 0 0 1 9.9 6.4–14.8
0 1 0 0 0 1 18.8 11.6–29.0
0 0 0 1 0 1 22.1 15.6–30.4
0 1 0 0 1 0 34.9 22.9–49.2
0 0 1 1 0 1 40.6 24.5–58.9
1 0 1 0 1 0 49.7 31.4–68.1
1 1 1 0 0 0 57.6 39.5–73.8
0 0 1 1 1 0 61.3 42.0–77.6
1 1 1 0 1 0 67.7 50.3–81.2
1 1 1 1 1 0 84.5 71.7–92.1
CXR, chest radiograph; adeno/large, adenocarcinoma or large cell; CI, confidence interval; 0 indicates that the finding is absent; 1 indicates that the finding is present.
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calculating posttest probabilities after CT. For example, we
previously demonstrated that the presence of lymph node
enlargement on CT (1 cm in short-axis diameter) has a
likelihood ratio of 2.8 for N2 metastasis. When we assume
that the estimated pretest probability of N2 metastasis is 67%,
and CT reveals enlarged lymph nodes, the pretest odds are 2
to 1, the posttest odds are 5.6 to 1 (2.8*2), and the updated
probability of metastasis is 85%. Parenthetically, the calcu-
lated posttest probability of metastasis in this patient is 96%
when the enlarged lymph nodes are hypermetabolic by PET.
Although some might argue that the accuracy of the
model was only fair to good, the area under the ROC curve
compares favorably with the accuracy of CT reported in
previous studies.9,25 Furthermore, our prediction model is not
intended to be used as a stand-alone diagnostic test but,
rather, as a tool to help guide the selection and interpretation
of subsequent diagnostic tests. Although cross-validation of
the model yielded a similar area under the curve, our results
still require external validation in an independent cohort of
patients with NSCLC.
In conclusion, we identified six independent predictors
of N2 metastasis in patients with NSCLC. N2 metastasis is
most likely in younger patients with large, symptomatic,
centrally located tumors; adenocarcinoma or large cell his-
tology; and/or suspected N2 metastasis on chest x-ray. The
pretest probability of N2 metastasis can be quantified using a
parsimonious clinical prediction equation that has the poten-
tial to facilitate clinical decision making in the staging of
patients with NSCLC.
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Suspected on CXR Adeno/Large Size >3.6 Age >65 Probability (%) 95% CI (%)
0 0 0 0 0 1 9.9 6.4–14.8
0 0 0 0 0 0 14.1 9.4–20.6
0 0 0 0 1 1 14.4 9.2–21.9
1 0 0 0 0 1 15.1 10.1–22.0
0 1 0 0 0 1 18.8 11.6–29.0
0 0 0 0 1 0 20.2 13.0–30.1
0 0 1 0 0 1 20.8 10.9–36.0
1 0 0 0 0 0 21.1 14.7–29.2
1 0 0 0 1 1 21.5 14.8–30.3
0 0 0 1 0 1 22.1 15.6–30.4
0 1 0 0 0 0 25.8 16.9–37.3
0 1 0 0 1 1 26.3 16.4–39.3
1 1 0 0 0 1 27.3 18.6–38.2
0 0 1 0 0 0 28.3 15.2–46.5
0 0 1 0 1 1 28.8 15.7–46.9
1 0 0 0 1 0 29.2 20.6–39.5
1 0 1 0 0 1 29.9 16.7–47.6
0 0 0 1 0 0 29.9 22.1–39.1
0 0 0 1 1 1 30.5 21.6–41.2
1 0 0 1 0 1 31.6 22.4–42.5
0 1 0 0 1 0 34.9 22.9–49.2
0 1 1 0 0 1 35.7 20.1–5.1
1 1 0 0 0 0 36.1 26.6–46.8
1 1 0 0 1 1 36.7 26.3–48.5
0 1 0 1 0 1 37.5 24.7–52.4
0 0 1 0 1 0 37.9 21.2–58.0
1 0 1 0 0 0 39.1 22.9–58.0
1 0 1 0 1 1 39.7 23.9–58.0
0 0 0 1 1 0 39.7 29.0–51.5
0 0 1 1 0 1 40.6 24.5–58.9
1 0 0 1 0 0 41.0 31.1–51.6
1 0 0 1 1 1 41.6 31.1–53.0
0 1 1 0 0 0 45.5 27.3–65.0
0 1 1 0 1 1 46.2 27.8–65.7
1 1 0 0 1 0 46.6 35.6–57.9
1 1 1 0 0 1 47.4 30.1–65.4
0 1 0 1 0 0 47.5 34.0–61.3
0 1 0 1 1 1 48.1 33.2–63.4
1 1 0 1 0 1 49.4 35.4–63.5
1 0 1 0 1 0 49.7 31.4–68.1
0 0 1 1 0 0 50.6 32.5–68.6
0 0 1 1 1 1 51.3 33.2–69.0
1 0 0 1 1 0 51.7 40.7–62.6
1 0 1 1 0 1 52.6 34.2–70.3
0 1 1 0 1 0 56.3 36.1–74.6
1 1 1 0 0 0 57.6 39.5–73.8
1 1 1 0 1 1 58.2 40.5–74.0
0 1 0 1 1 0 58.2 43.2–71.9
0 1 1 1 0 1 59.1 38.9–76.6
1 1 0 1 0 0 59.5 46.7–71.1
1 1 0 1 1 1 60.1 46.4–72.5
0 0 1 1 1 0 61.3 42.0–77.6
1 0 1 1 0 0 62.5 43.8–78.1
1 0 1 1 1 1 63.1 45.0–78.2
Shafazand and Gould Journal of Thoracic Oncology • Volume 1, Number 9, November 2006







Suspected on CXR Adeno/Large Size >3.6 Age >65 Probability (%) 95% CI (%)
1 1 1 0 1 0 67.7 50.3–81.2
0 1 1 1 0 0 68.4 49.0–83.1
0 1 1 1 1 1 69.0 49.5–83.5
1 1 0 1 1 0 69.4 57.4–79.2
1 1 1 1 0 1 70.1 51.5–83.8
1 0 1 1 1 0 72.0 54.7–84.6
0 1 1 1 1 0 77.0 59.3–88.5
1 1 1 1 0 0 77.9 61.9–88.4
1 1 1 1 1 1 78.4 62.8–88.6
1 1 1 1 1 0 84.5 71.7–92.1
CXR, chest radiograph; adeno/large, adenocarcinoma or large cell; CI, confidence interval.
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